119 related articles for article (PubMed ID: 37539729)
21. Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype.
Flink HJ; van Zonneveld M; Hansen BE; de Man RA; Schalm SW; Janssen HL;
Am J Gastroenterol; 2006 Feb; 101(2):297-303. PubMed ID: 16454834
[TBL] [Abstract][Full Text] [Related]
22. Chronic hepatitis B in pregnant women: is hepatitis B surface antigen quantification useful for viral load prediction?
Fujiko M; Chalid MT; Turyadi ; Ie SI; Maghfira ; Syafri ; Wahyuni R; Roni M; Patellongi I; Massi MN; Muljono DH
Int J Infect Dis; 2015 Dec; 41():83-9. PubMed ID: 26571304
[TBL] [Abstract][Full Text] [Related]
23. The importance of the serum quantitative levels of hepatitis B surface antigen and hepatitis B e antigen in children with chronic hepatitis B.
Demirören K; Kocamaz H; Doğan Y
Turk J Gastroenterol; 2015 Jan; 26(1):36-41. PubMed ID: 25698269
[TBL] [Abstract][Full Text] [Related]
24. HBsAg seroconversion after pegylated interferon alfa 2a rescue in a lamivudine-resistant patient with HBeAg-negative chronic hepatitis B and favourable IL28-B genotype.
Stanzione M; Stornaiuolo G; Rizzo V; Pontarelli A; Gaeta GB
Infez Med; 2016 Jun; 24(2):144-6. PubMed ID: 27367326
[TBL] [Abstract][Full Text] [Related]
25. [Low-levels of HBsAg quantification at 48-week in HBeAg-negative chronic hepatitis B patients are the advantageous population for HBsAg clearance].
Yan YJ; Wang XX; Cao ZH; Lu JF; Jin Y; He ZM; Geng N; Ren S; Ma LN; Chen XY
Zhonghua Gan Zang Bing Za Zhi; 2018 Nov; 26(11):813-818. PubMed ID: 30616314
[No Abstract] [Full Text] [Related]
26. [Observation of PD-1
He J; Yao YQ; Xia RX; Qiu TJ; Long L; Wang Y; Jiang Y
Zhonghua Gan Zang Bing Za Zhi; 2022 Mar; 30(3):316-322. PubMed ID: 35462489
[No Abstract] [Full Text] [Related]
27. Comparison of the 48-week efficacy of Lamivudine plus Adefovir or Entecavir monotherapy in patients with HBeAg negative hepatitis following Lamivudine treatment failure.
Zhang Q; Zhang L; Xing Y; Qin Y; Liu G
Acta Gastroenterol Belg; 2019; 82(1):31-34. PubMed ID: 30888751
[TBL] [Abstract][Full Text] [Related]
28. HBV mutations associated with lamivudine therapy.
Lapiński TW; Parfieniuk-Kowerda A; Trzos A; Jaroszewicz J; Kowalczuk O; Nikliński J; Flisiak R
Przegl Epidemiol; 2013; 67(4):611-6, 705-8. PubMed ID: 24741905
[TBL] [Abstract][Full Text] [Related]
29. [Factors associated with response to lamivudine: retrospective study of 233 patients with chronic hepatitis B].
Zhou HJ; Li SG; Wen FY; Yang XY; Wu JL; Tan B; Fu J
Zhonghua Gan Zang Bing Za Zhi; 2009 Aug; 17(8):564-8. PubMed ID: 19719911
[TBL] [Abstract][Full Text] [Related]
30. Analysis of intrahepatic total HBV DNA, cccDNA and serum HBsAg level in Chronic Hepatitis B patients with undetectable serum HBV DNA during oral antiviral therapy.
Li J; Sun X; Fang J; Wang C; Han G; Ren W
Clin Res Hepatol Gastroenterol; 2017 Dec; 41(6):635-643. PubMed ID: 28438570
[TBL] [Abstract][Full Text] [Related]
31. A prodrug of the capsid assembly modulator improved druggability and lowing HBsAg and HBeAg for the treatment of chronic hepatitis B.
Chen W; Gong Y; Long G; Wang X; Yang Y; Liu J; Li H; Tong X; Zhao Q; Yang L; Zuo J; Hu Y
Eur J Med Chem; 2023 Sep; 257():115485. PubMed ID: 37229833
[TBL] [Abstract][Full Text] [Related]
32. Quantitative detection of hepatitis B surface antigen by chemiluminescent microparticle immunoassay during lamivudine treatment of chronic hepatitis B virus carriers.
Kohmoto M; Enomoto M; Tamori A; Habu D; Takeda T; Kawada N; Sakaguchi H; Seki S; Shiomi S; Nishiguchi S
J Med Virol; 2005 Feb; 75(2):235-9. PubMed ID: 15602726
[TBL] [Abstract][Full Text] [Related]
33. Role of HBsAg decline in patients with chronic hepatitis B HBeAg-negative and E genotype treated with pegylated-interferon.
Boglione L; Cusato J; Cariti G; Di Perri G; D'Avolio A
Antiviral Res; 2016 Dec; 136():32-36. PubMed ID: 27793564
[TBL] [Abstract][Full Text] [Related]
34. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.
Lau GK; Piratvisuth T; Luo KX; Marcellin P; Thongsawat S; Cooksley G; Gane E; Fried MW; Chow WC; Paik SW; Chang WY; Berg T; Flisiak R; McCloud P; Pluck N;
N Engl J Med; 2005 Jun; 352(26):2682-95. PubMed ID: 15987917
[TBL] [Abstract][Full Text] [Related]
35. Effect of nucleos(t)ide analogue on serum HBsAg level in chronic hepatitis B patients: A 3-years study.
Zheng Z; Liao W; Liu L; Cai S; Zhu H; Yin S
Biomed Pharmacother; 2020 Feb; 122():109698. PubMed ID: 31918272
[TBL] [Abstract][Full Text] [Related]
36. Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy.
Seto WK; Wong DK; Fung J; Huang FY; Lai CL; Yuen MF
Hepatology; 2013 Sep; 58(3):923-31. PubMed ID: 23468172
[TBL] [Abstract][Full Text] [Related]
37. Preemptive adefovir versus lamivudine for prevention of hepatitis B reactivation in chronic hepatitis B patients undergoing chemotherapy.
Ho EY; Yau T; Rousseau F; Heathcote EJ; Lau GK
Hepatol Int; 2015 Apr; 9(2):224-30. PubMed ID: 25788197
[TBL] [Abstract][Full Text] [Related]
38. Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analog treatment in chronic hepatitis B: results from a nine-year longitudinal study.
Hosaka T; Suzuki F; Kobayashi M; Seko Y; Kawamura Y; Sezaki H; Akuta N; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
J Gastroenterol; 2013 Aug; 48(8):930-41. PubMed ID: 23065021
[TBL] [Abstract][Full Text] [Related]
39. Anti-hepatitis B virus activities of friedelolactones from Viola diffusa Ging.
Dai JJ; Tao HM; Min QX; Zhu QH
Phytomedicine; 2015 Jul; 22(7-8):724-9. PubMed ID: 26141758
[TBL] [Abstract][Full Text] [Related]
40. Intrahepatic distribution of hepatitis B virus antigens in patients with and without hepatocellular carcinoma.
Safaie P; Poongkunran M; Kuang PP; Javaid A; Jacobs C; Pohlmann R; Nasser I; Lau DT
World J Gastroenterol; 2016 Mar; 22(12):3404-11. PubMed ID: 27022222
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
